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Balanced control of neuronal activity is central in
maintaining function and viability of neuronal circuits.
The endocannabinoid system tightly controls neuro-
nal excitability. Here, we show that endocannabinoids
directly target hippocampal glutamatergic neurons to
provide protection against acute epileptiform seizures
in mice. Functional CB1 cannabinoid receptors are
present on glutamatergic terminals of the hippocam-
pal formation, colocalizing with vesicular glutamate
transporter 1 (VGluT1). Conditional deletion of the
CB1 gene either in cortical glutamatergic neurons or
in forebrain GABAergic neurons, as well as virally
induced deletion of the CB1 gene in the hippocampus,
demonstrate that the presence of CB1 receptors in glu-
tamatergic hippocampal neurons is both necessary
and sufficient to provide substantial endogenous pro-
tection against kainic acid (KA)-induced seizures. The
direct endocannabinoid-mediated control of hippo-
campal glutamatergic neurotransmission may consti-
tute a promising therapeutic target for the treatment
of disorders associated with excessive excitatory neu-
ronal activity.
Introduction
The endocannabinoid system is an important neuromo-
dulatory system involved in a plethora of physiological
functions (De Petrocellis et al., 2004; Freund et al.,
2003; Piomelli, 2003). It consists of cannabinoid recep-
tors, their endogenous lipid ligands (endocannabi-
noids), and the enzymatic machinery for their synthesis,
release, and degradation. To date, the only molecularly
characterized cannabinoid receptor expressed in fore-
brain neurons is the type 1 cannabinoid receptor, CB1
(Freund et al., 2003; Howlett et al., 2002), although phar-
macological approaches suggest the presence of addi-
tional neuronal cannabinoid receptors that have yet to
be fully characterized (Freund et al., 2003). Through ac-
tivation of CB1 receptors, the endocannabinoid system
exerts important functions in the central nervous sys-
tem, such as retrograde inhibition of neurotransmitter
release (Alger, 2002; Chevaleyre et al., 2006; Marsicano
and Lutz, 2006), control of neuronal excitability (Marsi-
cano et al., 2003), and regulation of various forms of
long-term synaptic plasticity (Chevaleyre et al., 2006;
Gerdeman and Lovinger, 2003; Marsicano and Lutz,
2006). In cortical areas, CB1 receptors are mainly
expressed by specific subpopulations of GABAergic in-
terneurons, where they are proposed to mediate both
endocannabinoid-dependent physiological regulation
of GABA transmission (Alger, 2002; Chevaleyre et al.,
2006; Freund et al., 2003) and pharmacological effects
of exogenous cannabinoids on GABA release (Freund
et al., 2003). Indeed, immunohistochemical studies in
cortical regions find CB1 receptor protein largely asso-
ciated with GABAergic interneurons (Egertova´ and
Elphick, 2000; Freund et al., 2003; Katona et al., 1999;
Tsou et al., 1998; Tsou et al., 1999), although discrepant
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456Figure 1. Specific Deletion ofCB1 in Different
Neuronal Subpopulations in Conditional CB1
Mutant Mice as Revealed by In Situ Hybrid-
ization with a Specific Riboprobe for CB1
mRNA
Micrographs showing CB1 mRNA expression
in the brain of CB1f/f (wt, [A]–[D]), CaMK-
CB12/2 (E–H), Glu-CB12/2 (I–L), and GABA-
CB12/2 mice (M–P). Sections were stained
throughout the brain and micrographs were
taken at the level of caudate putamen (A, E,
I, and M), dorsal hippocampus (B, F, J, and
N) and cerebellum (C, G, K, and O).
(D, H, L, and P) Detailed enlargements of the
dorsal hippocampus of (B), (F), (J), and (N), re-
spectively. In all three mutant lines, deletion
of CB1 is mainly restricted to the forebrain,
with little or no alterations in the hindbrain
(C, G, K, and O). In CaMK-CB12/2 mice,
CB1 mRNA is absent from all principal neu-
rons and expressed only in GABAergic inter-
neurons (intense scattered dots; E, F, and H).
In Glu-CB12/2 mice, CB1 mRNA is absent in
the majority of cortical glutamatergic neurons
(I, J, and L). In GABA-CB12/2 mice, CB1
mRNA is absent in all GABAergic neurons
and it is expressed only in non-GABAergic
cells (low uniform gray staining; M, N, and P).results have been reported (Domenici et al., 2006; Hoff-
man et al., 2005; Katona et al., 2006; Kawamura et al.,
2006; Ong and Mackie, 1999; Pettit et al., 1998; Takaha-
shi and Castillo, 2006). In fact, evidence was previously
reported for the presence of CB1 receptors in other neu-
ronal subtypes too, including glutamatergic principal
neurons. For instance, hippocampal principal neurons
express significant levels of CB1 mRNA, though at lower
levels than GABAergic interneurons (Marsicano and
Lutz, 1999; Matsuda et al., 1993). Given the general abil-
ity of CB1 receptors to reduce neuronal excitability
(Freund et al., 2003; Howlett et al., 2002; Lutz, 2004; Pio-
melli, 2003) and the increased kainic acid (KA)-induced
excitation in hippocampal pyramidal neurons in CB1
mutant mice, a direct control of glutamatergic transmis-
sion in the hippocampus has been proposed to mediate
the endocannabinoid-dependent on-demand protec-
tion against excitotoxicity (Marsicano et al., 2003).
However, conclusive evidence for a physiological or
pathophysiological function of CB1 receptors on hippo-
campal glutamatergic neurons has been elusive.
Excessive activation of glutamatergic transmission is
considered as a key pathogenic event leading to epilep-
tiform seizures, and glutamatergic circuits in the hippo-
campal formation are particularly prone to excessive
pathological activity (Ben-Ari and Cossart, 2000). Under-
standing the mechanisms regulating excitatory neuro-
transmission is mandatory to elucidate the pathophysi-
ology of important neurological disorders, such as
epilepsy and neurodegenerative diseases, and to gener-
ate novel therapeutic concepts for their treatment. Given
the central neuroprotective function of the endocanna-
binoid system in several models of neuronal insults
(Panikashvili et al., 2001; van der Stelt et al., 2002;
Lutz, 2004) and the proposed therapeutic exploitation
of this system for the treatment of several diseases (Di
Marzo et al., 2004; Mackie, 2006), it is of central impor-
tance to determine in detail which neuronal subtypesare controlled by the endogenous activation of CB1 re-
ceptors. Conditional mutagenesis using the Cre/loxP
system represents an optimal tool to dissect the specific
involvement of different neuronal populations in living
animals (Branda and Dymecki, 2004; Morozov et al.,
2003). In this study, we introduce novel conditional mu-
tants lacking the CB1 receptor in specific neuronal pop-
ulations and use the KA model of seizures (Ben-Ari and
Cossart, 2000) to provide functional and anatomical
evidence that CB1 receptors on hippocampal glutama-
tergic neurons are necessary for the CB1-dependent
protection against acute excitotoxic seizures.
Results
KA-Induced Seizures in Conditional CB1 Mutants
As compared to wild-type mice (Figures 1A–1D), condi-
tional mutant mice lacking CB1 expression from fore-
brain principal neurons express the receptor only in cor-
tical GABAergic interneurons and in nonforebrain
regions (CB1f/f;CaMKIIa-Cre mice, here called CaMK-
CB12/2 [CB12/2 in cells expressing the calcium/cal-
modulin-dependent kinase IIa, CaMKIIa]; Marsicano
et al., 2003; Figures 1E–1H) and show stronger seizures
following KA treatment as compared to wild-type (CB1f/f)
littermates (F1,24 = 13.5, p = 0.0012; Figure 2D). These
data confirm our previous results (Marsicano et al.,
2003) and suggest that glutamatergic cortical neurons
are the main target of CB1-dependent protection
against acute excitotoxic seizures. However, CaMK-
CB12/2 mice present a deletion of the CB1 gene not
only in cortical glutamatergic neurons, but also in many
neurons of subcortical and diencephalic regions, in-
cluding striatum, thalamus, and hypothalamus (Fig-
ures 1E and 1F), which might be involved in KA-induced
epileptiform seizures (Aparicio et al., 2004; Lee et al.,
2002; Nomura et al., 2000). Therefore, to obtain a more
Endocannabinoids Control Epileptogenic Circuits
457Figure 2. Deletion of CB1 in Glutamatergic Cortical Neurons, but Not in GABAergic Neurons, Increases Susceptibility to KA-Induced Seizures
(A–C) Micrographs showing double in situ hybridization of CB1 mRNA (red staining) together with GAD65 mRNA (silver grains) in the CA3 region
of CB1f/f (A), Glu-CB12/2 (B), and GABA-CB12/2 mice (C). In (A), CB1 is present in both GABAergic interneurons and pyramidal neurons. In (B),
CB1 is present only in GABAergic interneurons. In (C), CB1 is present only in pyramidal neurons. Blue staining, toluidine blue nuclear counter-
staining. Filled arrows, GABAergic interneurons (GAD65-positive) expressing CB1 mRNA. Open arrows, GABAergic interneurons lacking CB1
expression. Bar, 25 mm. For similar analysis of CB1 expression in CaMK-CB12/2 mice, see Figure 2 of Marsicano et al. (2003).
(D–F) Seizure scoring (30 mg/kg KA) of conditional CB1 mutant mice (filled symbols), as compared to control CB1f/f littermates (open symbols).
Seizures are worsened in CaMK-CB12/2 (D) and in Glu-CB12/2 (E), whereas they do not differ from wild-type controls in GABA-CB12/2mice (F).
In brackets, number of animals for each experimental group. Data are presented as mean6 SEM. **p < 0.005; ***p < 0.001 (by two-way ANOVA,
factor genotype).selective deletion of CB1 receptors in glutamatergic cor-
tical neurons, we crossed CB1f/f with NEX-Cre mice
(Kleppisch et al., 2003; Wu et al., 2005; see Supplemental
Data available with this article online; Figure S1), to ob-
tain the double mutants CB1f/f;NEX-Cre. In these mice
(hereafter called Glu-CB12/2), CB1 expression is absent
in the majority of cortical glutamatergic neurons, includ-
ing hippocampus, neocortex, and amygdala, whereas
GABAergic interneurons and other subcortical neurons
express normal levels of the receptor (Figures 1I–1L).
Double in situ hybridization experiments, combining
visualization and quantification of CB1 and glutamic
acid decarboxylase 65 kDa (GAD65, a marker of
GABAergic neurons) mRNA expression in Glu-CB12/2
mice, revealed that more than 99% of CB1-positive cells
coexpress GAD65 mRNA in the whole hippocampal for-
mation, indicating a loss of expression in adjacent gluta-
matergic neurons (Figures 2A and 2B). Furthermore,
39.2% 6 3.8% of GAD65-positive cells express CB1
mRNA, similarly to wild-type (CB1f/f, 38.7% 6 6.9%;
see also Marsicano and Lutz [1999]), suggesting that
CB1 expression in GABAergic neurons is unaffected in
Glu-CB12/2 mice. Treatment of Glu-CB12/2 mice with
30 mg/kg of KA induced stronger seizures as compared
to CB1f/f littermates, thus revealing the essential role of
cortical glutamatergic principal neurons in CB1-depen-
dent protection against KA-induced seizures (F1,29 =
24.1, p < 0.001; Figure 2E). To definitely exclude the in-
volvement of GABAergic neurons in this function of the
endocannabinoid system, we generated an additional
conditional CB1 mutant mouse line, in which CB1 ex-
pression is abolished in GABAergic neurons. CB1f/f
mice were crossed with Dlx5/6-Cre mice (Figures 1M–
1P and S2 and S3; Supplemental Data). CB1f/f;Dlx5/6-Cremice (hereafter called GABA-CB12/2) lack expression
of CB1 in virtually all the GABAergic neurons of the fore-
brain (Figures 1M–1P). In particular, in the hippocampal
formation, more than 99% of GAD65-positive cells lack
coexpression with CB1 mRNA (Figure 2C). Interestingly,
treatment of these mice with 30 mg/kg KA induced
similar levels of seizures as in CB1f/f littermate controls
(F1,18 = 0.1, p = 0.76; Figure 2F).
These results clearly show that expression of CB1 re-
ceptors in GABAergic cells does not play a significant
role in the physiological protection against acute KA-
induced seizures, whereas cortical glutamatergic neu-
rons mediate the protective functions of the endocanna-
binoid system.
CB1 Receptors Directly Control GABAergic
Transmission but Are Dispensable for
Pharmacological GABA-Mediated Protection
against KA-Induced Seizures
As CB1 receptors are well known to control GABAergic
transmission (Chevaleyre et al., 2006; Alger, 2002;
Freund et al., 2003), the absence of a phenotype in
GABA-CB12/2 mice is a surprising result. Therefore,
we performed experiments aimed at confirming (1) the
absence of CB1-mediated effects on GABAergic trans-
mission in GABA-CB12/2mice and (2) the independence
from CB1 receptors of GABA-mediated protection
against KA-induced seizures, as induced by the alloste-
ric GABA-A receptor enhancer diazepam (Mo¨hler et al.,
2002).
To this end, we first tested the CB1-mediated retro-
grade regulation of GABAergic transmission (Wilson
et al., 2001) in hippocampal slices derived from GABA-
CB12/2 and CaMK-CB12/2 mice and the respective
Neuron
458Figure 3. Functions of CB1 Receptors in the
Control of GABAergic Transmission in Condi-
tional CB1 Mutant Mice and in the Develop-
ment of KA-Induced Seizures
(A) Depolarization-induced suppression of in-
hibitory currents (DSI) in CA1 hippocampal
pyramidal neurons of CaMK-CB12/2 mice
(filled circles, n = 11 cells from six mice) and
of respective CB1f/f littermate controls
(open circles, n = 13 cells from six mice).
The 5 s depolarization step is indicated (see
Experimental Procedures). Data are mean 6
SEM.
(B) Summary of DSI data obtained by calcu-
lating the mean of the five eIPSCs before
and after the depolarization step. Data are
mean 6 SEM. Top, representative traces be-
fore and after depolarization step for each
genotype, respectively. Data are mean 6
SEM. ***p < 0.001 versus respective baseline
before depolarization (100%, dotted line).
(C) DSI in CA1 hippocampal pyramidal neu-
rons of GABA-CB12/2 (filled triangles, n =
13 cells from six mice) and of respective
CB1f/f littermate controls (open triangles,
n = 10 cells from six mice). Data are mean 6
SEM. The 5 s depolarization step is indicated.
(D) Summary of DSI data obtained by calcu-
lating the mean of the five eIPSCs before
and after the depolarization step. Top, repre-
sentative traces before and after depolariza-
tion step for each genotype, respectively.
Data are mean 6 SEM. ***p < 0.001 versus
respective baseline before depolarization
(100%, dotted line).
(E) Effects of vehicle (open symbols) and of
the allosteric modulator of GABA-A receptor
diazepam (6 mg/kg, filled symbols) on KA-
induced seizures in CB1+/+ (triangles) and
on CB12/2 littermates (squares). Data are
mean 6 SEM. **p < 0.01 as compared to
respective vehicle-treated groups (by two-
way ANOVA, factor treatment).CB1f/f controls. Pharmacologically isolated GABAergic
currents were recorded in CA1 hippocampal pyramidal
neurons. After a 5 s postsynaptic depolarization step,
a reliable short-term decrease of inhibitory currents
(depolarization-induced suppression of inhibition, DSI;
Wilson et al., 2001) was observed in the two CB1f/f con-
trol groups (Figures 3A–3D). As expected, in CaMK-
CB12/2 slices, DSI was undistinguishable from CB1f/f
controls (Figures 3A and 3B). However, DSI was abol-
ished in GABA-CB12/2mice (Figures 3C and 3D). There-
fore, retrograde CB1-dependent short-term control of
GABAergic transmission in the hippocampus entirely
relies on the expression of CB1 on GABAergic interneu-
rons and, importantly, these data demonstrate that this
function is abolished in GABA-CB12/2 mice.
We next asked whether the KA-induced increase in in-
hibitory GABAergic transmission in the hippocampus
(Ben-Ari and Cossart, 2000) is influenced by the endo-
cannabinoid system. Benzodiazepines are allosteric
modulators of GABA-A receptors that act as potent
anticonvulsants by enhancing the inhibitory effects of
GABAergic transmission (Mo¨hler et al., 2002). If the en-
docannabinoid system modulates release of GABA dur-
ing KA-induced seizures, the anticonvulsant effects of
the prototypical benzodiazepine diazepam should be al-tered in mutant mice lacking CB1 expression in all cells
(Marsicano et al., 2002). In accordance with our previous
findings (Marsicano et al., 2003), CB12/2 mice were
highly susceptible to KA-induced seizures as compared
to control wild-type littermates (CB1+/+; Figure 3E).
However, the injection of 6 mg/kg diazepam protected
both CB1+/+ and CB12/2 littermates to the same extent
against KA-induced seizures (Figure 3E). Pretreatment
with diazepam might cause a general strong increase
of basal GABAergic transmission, which might mask
the CB1-dependent influence during KA-induced sei-
zures. To rule out this possibility, we treated CB1+/+
and CB12/2 mice with 6 mg/kg diazepam after the oc-
currence of first seizures (behavioral score 4). In these
conditions too, diazepam protected both genotypes
to similar extent and reduced mortality of CB12/2 mice
to levels indistinguishable from CB1+/+ controls
(Figure S4).
Altogether, these results confirm that physiological
endocannabinoid-dependent control of GABAergic
transmission depends on intact CB1 signaling in
GABAergic interneurons and suggest that the endocan-
nabinoid system does not influence GABAergic trans-
mission during the development of KA-induced sei-
zures. Therefore, direct modulation of glutamatergic
Endocannabinoids Control Epileptogenic Circuits
459Figure 4. CB1 Protein Is Present in Glutama-
tergic Hippocampal Neurons
Micrographs showing the immunohisto-
chemical analysis of CB1 expression in
wild-type (A–C), CaMK-CB12/2 (D–F),
GABA-CB12/2 (G–I) and complete CB1
knock-out mice (J–L).
(B, E, H, and K) Higher magnification micro-
graphs of the areas enclosed in the square
in (A), (D), (G), and (J), respectively.
(C, F, I, and L) Detail of the CA3 hippocampal
region.
GC, granule cell layer of dentate gyrus; Hil,
hilar region of dentate gyrus; LMol, stratum
lacunosum-molecularis; Mol, stratum mo-
lecularis; Or, stratum oriens; Pyr, CA1/CA3
pyramidal cell layer of hippocampus; Rad,
stratum radiatum. Asterisks indicate the inner
third of the molecular layer. Bar, 100 mm (A, C,
D, F, G, I, J, and L); 25 mm (B, E, H, and K).transmission by CB1 receptors expressed on cortical
glutamatergic neurons appears to be the major mecha-
nism of endocannabinoid-mediated protection against
KA-induced seizures.
The Inner Molecular Layer of Dentate Gyrus
Contains CB1 Receptor Protein
In order to investigate the location of CB1 receptors
involved in the protection against KA-induced seizures,
we performed a detailed analysis of CB1 expression
in the hippocampal formation of GABA-CB12/2, CaMK-
CB12/2, and CB1f/f controls (where CB1 expression is
not different from wild-type C57BL/6N mice, see Experi-
mental Procedures). In CB1f/f mice, immunohistochem-
istry for CB1 protein revealed the well-described
wild-type expression pattern, with intense staining of
GABAergic terminals mainly belonging to basket cells
and lack of CB1 expression in pyramidal and granule
cell bodies (Egertova´ and Elphick, 2000; Freund et al.,
2003; Katona et al., 1999; Tsou et al., 1998; Tsou et al.,
1999; Figures 4A–4C). In conditional CaMK-CB12/2
hippocampi, CB1 protein expression is still present in
GABAergic terminals surrounding pyramidal and gran-
ule cell bodies (Figures 4D–4F). However, clear differ-
ences emerge in the pattern of CB1 expression in
CaMK-CB12/2 mice as compared to wild-type. In the
conditional mutant mice, the staining appears much
less uniform and much more localized to punctae and fi-
bers (Figures 4D–4F). The intensity of the signal is also
lower as compared to wild-type, particularly in extrapy-
ramidal CA1 and CA3 regions and extragranular dentate
layers, such as the strata molecularis (Figures 4D–4F),radiatum, and oriens (Figures 4D and 4F). In the hippo-
campal formation of GABA-CB12/2 mice, the overall
CB1 staining is strongly decreased as compared to
wild-type. In particular, the intense network of CB1
staining, corresponding to interneuron basket cell termi-
nals (Egertova´ and Elphick, 2000; Freund et al., 2003;
Katona et al., 1999; Tsou et al., 1998; Tsou et al., 1999),
surrounding pyramidal and granule cells is absent (Fig-
ures 4G–4I). However, residual CB1 labeling is present
in the hippocampal formation of GABA-CB12/2 mice
(for comparison, see staining of complete CB1 knockout
mice, Figures 4J–4L). The staining appears much more
diffuse and less localized to easily identifiable fibers
than in wild-type and CaMK-CB12/2 hippocampi.
Weak CB1 labeling is present in the strata molecularis
(Figures 4G and 4H), radiatum, and oriens of the CA1
and CA3 region of GABA-CB12/2 mice (Figures 4G and
4I). Interestingly, these areas are the same in which a de-
creased CB1 expression is observed in CaMK-CB12/2
mice, suggesting that the complementary CB1 expres-
sion in these two mutant lines observed at mRNA level
(Figure 1), is also present at protein level. The strongest
CB1 expression in the hippocampal formation of GABA-
CB12/2mice is present in the inner third of the molecular
layer of dentate gyrus, represented by diffuse immuno-
labeling throughout the whole subregion (Figures 4G
and 4H). Interestingly, the expression of CB1 in this
subregion of CaMK-CB12/2 mice (Figure 4E) is not
only strongly reduced as compared to wild-type (Fig-
ure 4B), but is also different in terms of staining pattern.
By careful observation, one can notice that the ‘‘sum’’
of GABA-CB12/2 (low and diffuse; Figure 4H) and
Neuron
460CaMK-CB12/2 patterns (high and punctate; Figure 4E)
would approximate wild-type staining, where both these
features are present (Figure 4B). Semiquantitative anal-
ysis of immunostaining in the inner molecular layer re-
vealed that the intensity of staining in the inner molecu-
lar layer reached 150.4 6 5.3 relative intensity units in
the wild-type hippocampus and was reduced to 85.0 6
1.5 and to 52.2 6 1.0 in CaMK-CB12/2 and in GABA-
CB12/2, respectively. Therefore, in the inner third of
the molecular layer, mice lacking CB1 on GABAergic
neurons (GABA-CB12/2mice) still retain CB1 protein ex-
pression, strongly suggesting that CB1 receptors are
expressed on glutamatergic terminals in this area.
Dentate Gyrus Hilar Mossy Cells Express
Functional CB1 Receptors
The inner third of the dentate gyrus molecular layer con-
sists of sparse interneurons and of the initial part of the
dendritic arbor of the granule cells of dentate gyrus
(Johnston and Amaral, 2004). Granule cells receive glu-
tamatergic inputs primarily from perforant path fibers
originating in the entorhinal cortex, from a portion of glu-
tamatergic neurons of the CA3 region (Li et al., 1994) and
from mossy cells, which represent the great majority of
non-GABAergic neurons in the hilus of dentate gyrus
(Johnston and Amaral, 2004). These projections to
granule cell dendrites are spatially segregated, with
perforant path terminals mainly occupying the outer
two-thirds of the molecular layer and mossy cells mainly
contributing to the glutamatergic afferent fibers in the in-
ner third of this region (Johnston and Amaral, 2004).
Therefore, we hypothesized that the intense CB1 band
in this subregion (Figures 4B, 4C, and 4H) might in part
belong to mossy cell terminals or axons, which, there-
fore, should express CB1 mRNA in their cell bodies. To
test this notion, double in situ hybridization experiments
were performed in wild-type mice using a combination
of riboprobes specific for CB1 and vesicular glutamate
transporter 1 (VGluT1) mRNA. VGluT1 is a protein that
participates in the recycling of glutamate into synaptic
vesicles of glutamatergic neurons, and it currently repre-
sents the best available marker for cortical glutamater-
gic neurons (Fremeau et al., 2004). Double in situ hybrid-
ization staining of wild-type mouse brains revealed
a very high degree of coexpression of CB1 and VGluT1
in all cortical regions, as exemplified in CA3 hippocam-
pal pyramidal neurons, basolateral amygdala, and ento-
rhinal cortex (Figures 5A–5C). VGluT1 mRNA is present
in virtually all neurons expressing low levels of CB1
mRNA, which are known as non-GAD65-expressing pu-
tative glutamatergic cells (Marsicano and Lutz, 1999).
Detailed analysis of the hilus of dentate gyrus, where
cell bodies of mossy cells are located, also revealed
high degree of coexpression in glutamatergic mossy
cells (Figure 5D). The great majority (92.0% 6 7.3%) of
VGluT1-positive mossy cells expresses low levels of
CB1 mRNA and 96.6% 6 3.2% of low CB1-expressing
cells contain VGluT1 mRNA, suggesting that much of
the CB1 protein observed in the inner third of the molec-
ular layer is on mossy cell terminals. Indeed, glutamater-
gic mossy cells express CB1 mRNA in wild-type and
GABA-CB12/2 mice (Figures 5E and 5F), whereas all
CB1-expressing neurons in the hilus of CaMK-CB12/2
and Glu-CB12/2 mice coexpress GAD65 (Figures 5Gand 5H), showing loss of CB1 expression in glutamater-
gic mossy cells in these two mouse lines.
To analyze the subcellular localization of CB1 protein
in mossy cells, we performed double-label immunohis-
tochemistry using specific antibodies against CB1 and
VGluT1. The expression of VGluT1 in the hippocampal
formation was similar as previously described (Kaneko
et al., 2002), with strong labeling of all hippocampal
layers, excluding pyramidal and granule cell bodies (Fig-
ure 6A). Confocal analysis of double CB1/VGluT1 stain-
ing in the inner third of the molecular layer revealed a
very high degree of coexpression of the two proteins
(Figures 6B–6D). 62%62%of terminals in this regioncon-
tain CB1 protein, whereas 94%6 1% of visible terminals
are VGluT1 positive. Consistently, coexpression of CB1
and VGluT1 was observed in 91%6 1% of CB1-positive
terminals and in 59% 6 2% of VGluT1-positive ones.
To test for the functionality of these CB1 receptors,
evoked glutamatergic currents in granule cells of the
dentate gyrus in hippocampal slices were recorded by
whole-cell patch-clamp. To generate evoked excitatory
postsynaptic currents (eEPSCs), the stimulation elec-
trode was placed next to the recorded granule cell in
the inner molecular layer. Bath application of the CB1
agonist WIN55,212-2 to slices prepared from wild-type
mice (CB1f/f) induced a progressive decrease in eEPSC
amplitude, which reached 77.9% 6 4.5% of baseline 40
min after drug application (p < 0.01 as compared to
baseline; Figures 6E–6G). Conversely, bath application
of WIN55,212-2 to slices prepared from CaMK-CB12/2
mice did not significantly affect granule cell eEPSC am-
plitude (108.4% 6 18.4% of baseline, p = 0.66; Figures
6E–6G).
Altogether, these data show that functional CB1 pro-
tein is abundantly present on glutamatergic terminals
in the inner third of the molecular layer of dentate gyrus,
which represent a very well-suited locus to exert tight
regulation of hippocampal excitability.
Virally Induced Deletion of CB1 Gene in the
Hippocampus and KA-Induced Seizures
The residual expression of CB1 in glutamatergic hippo-
campal terminals in GABA-CB12/2 mice might account
for the normal protection against KA-induced seizures
in this mutant mouse line. However, in GABA-CB12/2
mice, CB1 is still expressed in other cortical and subcor-
tical neurons (Figures 1M and 1N), leaving open the pos-
sibility that glutamatergic hippocampal neurons play
only a secondary role in this function of the endocanna-
binoid system. To rule out this possibility, we injected an
adeno-associated virus expressing Cre-recombinase
(AAV-Cre) or green fluorescent protein (AAV-GFP), as
a negative control, bilaterally into the hilus of dentate
gyrus of CB1f/f mice. Injection of AAV-GFP did not in-
duce any change in the expression of CB1 mRNA (Fig-
ure 7A), whereas AAV-Cre induced a complete deletion
of CB1 gene in the hilus of dentate gyrus and in part of
the CA3 and CA1 regions of the hippocampus (Figures
7B and 7C). Importantly, expression of the receptor in
adjacent regions, such as the neocortex, or the lateral
habenula was unaffected (Figures 7A and 7B).
CB1f/f mice injected with either virus were treated with
30 mg/kg KA, and seizures were monitored. AAV-GFP-
injected mice showed levels of seizures very similar to
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461Figure 5. CB1 mRNA Is Expressed in Gluta-
matergic Cortical Neurons and in Glutamater-
gic Mossy Cells of the Dentate Gyrus, as Re-
vealed by Double In Situ Hybridization
Experiments in Wild-Type C57BL/6N Mice
and Conditional Mutants
(A–D) Micrographs showing coexpression of
CB1 mRNA (red staining) with VGluT1
mRNA (silver grains) in the CA3 region of
hippocampus (A), basolateral amygdala (B),
entorhinal cortex (C), and hilus of dentate gy-
rus (D) of wild-type C57BL/6N adult mice.
Filled arrows, GABAergic interneurons, ex-
pressing CB1, but not VGluT1. Open arrows,
glutamatergic neurons, coexpressing CB1
and VGluT1.
(E–H) Micrographs showing coexpression of
CB1 mRNA (red staining) with GAD65 mRNA
(silver grains), in the hilus of dentate gyrus
in CB1f/f (E), GABA-CB12/2 (F), CaMK-
CB12/2 (G), and Glu-CB12/2 mice (H). Filled
arrowheads, GABAergic interneurons, coex-
pressing CB1 and GAD65 mRNAs. Open
arrowheads, presumable glutamatergic neu-
rons, not coexpressing CB1 and GAD65
mRNAs.
Note that high CB1-expressing cells do not
coexpress VGluT1 mRNA (A–D), but do coex-
press GAD65 mRNA (E–H), showing that they
are GABAergic interneurons. Conversely, low
CB1-expressing cells coexpress VGluT1
mRNA (A–D), but do not contain GAD65
mRNA (E–H), showing that they are glutama-
tergic neurons. In particular, glutamatergic
hilar mossy cells contain CB1 mRNA in wild-
type (D), CB1f/f mice (E), and GABA-CB12/2
(F), but not in CaMK-CB12/2 (G) and Glu-
CB12/2 mice (H). Blue staining, toluidine
blue nuclear counterstaining. GC, granule
cells of dentate gyrus. Pyr, CA3 pyramidal
neurons. Bar, 25 mm.wild-type mice (Figure 7D, see also Figures 2D–2F),
whereas hippocampal injection of AAV-Cre induced
a strong worsening of seizures (F1,16 = 4.6; p < 0.05;
Figure 7D). Importantly, we previously showed that
expression of Cre-recombinase in principal forebrain
neurons per se does not alter susceptibility to KA-
induced seizures (Marsicano et al., 2003). Altogether,
these results indicate that local deletion of CB1 in the
hippocampal formation strongly reduces on-demand
protection against KA-induced acute seizures.
Discussion
Normal neuronal computation in the brain requires in-
tense ongoing excitatory transmission. However, exces-
sive excitatory activity results in neuronal damage and
death, through a mechanism known as excitotoxicity(Ben-Ari and Cossart, 2000). The spreading of excessive
uncontrolled glutamatergic neurotransmission eventu-
ally leads to sustained, paroxysmal network activity cul-
minating in behaviorally observable symptoms, such as
seizures. Similar mechanisms might underlie important
human neurological diseases, including various forms
of epilepsy (Ben-Ari and Cossart, 2000). Therefore, neu-
ronal circuits need very efficient control systems to limit
the danger of excessive excitatory activity. The endo-
cannabinoid system represents one of these systems.
Indeed, KA-induced seizures are accompanied by
a rapid increase of production of the endocannabinoid
anandamide in the hippocampus and activation of CB1
cannabinoid receptors, necessary for the protection
against acute excitotoxicity and for the induction of
protective intracellular signaling cascades (Marsicano
et al., 2003). However, the nature of the neuronal
Neuron
462Figure 6. Glutamatergic Terminals of Mossy
Cells Contain Functional CB1 Receptors
(A) Low-magnification micrograph showing
expression of VGluT1 protein in the hippo-
campal formation.
(B–D) High-magnification confocal micro-
graphs showing detailed expression of CB1
and VGluT1 protein in the inner third of the
molecular layer (approximately correspond-
ing to the dotted area in [A]). Expression of
VGluT1 (green, [B]), CB1 (red, [C]), and
merged image (D) are shown. Yellow areas in-
dicate colocalization of the two proteins.
(E–G) Activation of CB1 receptors reduces
glutamatergic inputs onto dentate gyrus
granule cells.
(E) Time-course analysis of the effects of
5 mM of the CB1 agonist WIN55,212-2 on
eEPSCs in wild-type (CB1f/f, open circles,
n = 6 slices from three mice) and CaMK-
CB12/2 littermates (filled circles, n = 6 cells
from three mice).
(F) Summary of eEPSCs data obtained by cal-
culating the average of the measurements
obtained during the last 5 min of experiment
(35–40 min after drug application).
(G) Representativeelectrophysiological traces
before (baseline) and 40 min after application
of WIN 55,212-2 (WIN).
Bars, 75 mm (A), 3.5 mm (B–D); **p < 0.01 as
compared to baseline (average of the mea-
surements during the last 5 min before drug
application, dotted line).subpopulations under the functional control of the endo-
cannabinoid system has been subject of considerable
debate (Freund et al., 2003; Ha´jos et al., 2001; Katona
et al., 1999; but see Domenici et al., 2006; Katona
et al., 2006; Kawamura et al., 2006; Marsicano and
Lutz, 1999; Matsuda et al., 1993; Takahashi and Castillo,
2006). In the present study, we used a systematic ge-netic approach aimed at dissecting the roles of different
neuronal subpopulations in the protective functions
of the endocannabinoid system against KA-induced
seizures.
Our results clearly show that hippocampal glutama-
tergic neurons, where CB1 receptors are present at
low but detectable levels, are the central mediatorsFigure 7. Virally Induced Deletion of CB1
Gene in the Hippocampal Formation In-
creases the Sensitivity to KA-Induced
Seizures
(A and B) Dark-field micrographs showing
CB1 mRNA expression inCB1f/f mice 9 weeks
after intrahilar injections of AAV-GFP (A) and
of AAV-Cre (B), showing the Cre-mediated
deletion of CB1 in the hilus of the dentate
gyrus and in part of the CA1 and CA3 hippo-
campal regions. Cx, neocortex; Lh, lateral
habenula; bar, 500 mm.
(C) Schematic diagrams showing the approx-
imate extension of Cre-mediated recom-
bination of CB1 (gray shading) in AAV-
Cre-injected CB1f/f mice (see Experimental
Procedures). Numbers, distance from
bregma (Paxinos and Franklin, 2001).
(D) Seizure scoring (30 mg/kg of KA) of
AAV-GFP-injected (open circles) and AAV-
Cre-injected CB1f/f mice (filled circles). In
brackets, number of mice in each experimen-
tal group. Data are presented as mean 6
SEM. *p < 0.05, by two-way ANOVA.
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463of on-demand endocannabinoid-dependent protection
against KA-induced acute excitotoxic seizures. Further-
more, although the presence of CB1 receptors on GA-
BAergic neurons is necessary for endocannabinoid-de-
pendent forms of short-term plasticity of inhibitory
transmission (DSI), the abundant expression of CB1 on
GABAergic interneurons does not play a role in the
endocannabinoid-dependent protection against KA-
induced seizures.
The pharmacological protection given by the GABA-A
allosteric enhancer diazepam does not seem to be influ-
enced by CB1 receptors. This further suggests that
GABAergic transmission during acute KA-induced sei-
zures is independent from CB1 receptor-mediated con-
trol. However, given the only partial inhibition of GABA
release by CB1 receptor activation, the possibility that
the strong enhancement of postsynaptic GABA signal-
ing by diazepam could compensate for the CB1 recep-
tor-mediated reduction of GABA release cannot be ruled
out at this point.
Dentate gyrus mossy cells and hippocampal pyrami-
dal neurons express CB1 mRNA and functional CB1 pro-
tein is present in the inner molecular layer of dentate
gyrus, associated with glutamatergic terminals. The
presence of CB1 protein in this area in GABA-CB12/2
mice suggests that this location might be an important
target for on-demand endocannabinoid-mediated pro-
tection against KA-induced seizures. Mossy cells are
centrally involved in epileptiform seizure development
(Ratzliff et al., 2002). These glutamatergic neurons are
situated in the hilar portion of the dentate gyrus and re-
ceive intense glutamatergic inputs from dentate granule
cells (Johnston and Amaral, 2004). In turn, they innervate
ipsilateral and contralateral GABAergic interneurons
and send back projections to a large number of granule
cells along the longitudinal axis of the hippocampal for-
mation (Johnston and Amaral, 2004; Ratzliff et al., 2002).
This strategic position suggests that the glutamatergic
loop between granule and mossy cells is centrally in-
volved in the modulation of excitatory activity of hippo-
campal circuits and in the regulation of information in-
flux into the hippocampal formation. Our finding that
the inner molecular layer of the dentate gyrus, where
mossy cell terminals synapse onto granule cells, con-
tains functional CB1 receptors represents a novel step
in understanding the progression of acute excitotoxic
seizures and the development of epileptic states. How-
ever, it should be mentioned that the inner molecular
layer of dentate gyrus receives glutamatergic inputs
not only from mossy cells (Johnston and Amaral,
2004), but also from CA3 pyramidal neurons (Li et al.,
1994). Both these neuronal types express CB1 mRNA
(Figures 2A and 5A), indicating that the presence of
CB1 protein in the inner molecular layer is carried by ax-
onal terminals of both these glutamatergic hippocampal
neuronal populations. Moreover, low but significant
levels of CB1 protein are still present in extrapyramidal
layers of the CA1 and CA3 hippocampal region of
GABA-CB12/2 mice. Therefore, a parsimonious inter-
pretation of the present data is that the endocannabi-
noid system strongly controls key glutamatergic cir-
cuitry in the hippocampal formation during KA-induced
seizures, likely regulating both mossy cell and pyramidal
neuron transmission.The presence of CB1 receptors in cortical glutamater-
gic neurons has been vigorously debated in recent
years, and the cannabinoid effects on glutamatergic
transmission have been proposed to depend on novel
non-CB1/non-CB2 cannabinoid receptors (Freund
et al., 2003; Ha´jos et al., 2001; but see Domenici et al.,
2006; Takahashi and Castillo, 2006). Our data clearly
show that CB1 on hippocampal glutamatergic neurons
plays a central role during acute KA-induced behavioral
seizures, thus demonstrating the functional importance
of this location of CB1 receptors.
Deletion of CB1 receptors in GABAergic neurons in
GABA-CB12/2 mice, where endocannabinoid-mediated
DSI in the hippocampus is abolished, does not alter the
behavioral seizure response to KA. Considering that the
endocannabinoid system controls a portion of GABA-
ergic transmission in the hippocampus (Chevaleyre
et al., 2006; Alger, 2002; Freund et al., 2003; Marsicano
and Lutz, 2006; present results) and that GABAergic in-
terneurons are intensely activated during KA-induced
seizures (Ben-Ari and Cossart, 2000), this is a surprising
result. The reasons of this lack of involvement of
GABAergic interneurons in the CB1 receptor-dependent
control of behavioral KA-induced seizures by the endo-
cannabinoid system are not clear at the moment. How-
ever, a recent publication by Fo¨ldy et al. (2006) showed
that the CB1 receptor-dependent control of GABAergic
transmission in the hippocampus is strictly regulated by
the firing rate of the presynaptic GABAergic interneuron.
CB1 agonist- and endocannabinoid-dependent reduc-
tion of GABAergic transmission is strongly reduced
when the firing rate of the presynaptic interneuron is
above a certain threshold. Kainic acid, mainly through
the activation of GluR5-containing KA receptors, directly
and strongly increases the firing rate of GABAergic inter-
neurons (Ben-Ari and Cossart, 2000). Therefore, it is
possible that, in the presence of seizure-inducing doses
of KA, GABAergic interneurons fire at frequencies that
are sufficient to free them from the control of the endo-
cannabinoid system (Fo¨ldy et al., 2006).
Altogether, these observations support a hypothetical
scenario in which acute KA-induced excitotoxic sei-
zures would activate the endocannabinoid system in re-
spect to its ability to inhibit only ‘‘harmful’’ glutamatergic
transmission, but not ‘‘protective’’ GABAergic release.
In conclusion, our study reveals a mechanism through
which the endocannabinoid system is able to provide
on-demand protection against acute behavioral sei-
zures. CB1 expression on hippocampal glutamatergic
circuits accounts for this protection and might represent
a suitable target for the treatment of neurological disor-
ders associated with excessive neuronal excitation.
Experimental Procedures
Animals
Male mice were used in all experiments, aged 2–5 months, main-
tained in standard conditions with food and water ad libitum. All ex-
perimental procedures were approved by the Committees on Animal
Health and Care of local governments. C57BL/6NCrlBR mice were
purchased from Charles River. CD1 mice (for colocalization of
VGluT1 and CB1) were purchased from Jackson Laboratory. Condi-
tional CB1 mutant mice were obtained by crossing the respective
Cre-expressing mouse line with CB1f/f mice (Marsicano et al.,
2003), using a three-step breeding protocol. CB1f/f;CaMKIIa-Cre mice
Neuron
464(here called CaMK-CB12/2) were obtained as described (Marsicano
et al., 2003). CB1f/f;NEX-Cre mice (here called Glu-CB12/2) were ob-
tained by crossing CB1f/f with NEX-Cre mice (Kleppisch et al.,
2003; Schwab et al., 2000; Wu et al., 2005). Genotyping was per-
formed by PCR as described for CaMK-CB12/2 (Marsicano et al.,
2003), for Glu-CB12/2 (Kleppisch et al., 2003), and for CB1f/f (Marsi-
cano et al., 2003). CB1+/+ and CB12/2mice were generated and gen-
otyped as described (Marsicano et al., 2002). All lines were in a mixed
genetic background, with a predominant C57BL/6NCrlBR contribu-
tion. All animals used in single experiments were littermates. Exper-
imenters were always blind to genotype and/or treatment.
Generation of GABA-CB12/2 Mice
In order to express the Cre-recombinase with patterns that resemble
that of the mouse Dlx5/Dlx6 genes, we placed the Cre gene under
the control of the I56i and I56ii intergenic enhancer sequences (Zer-
ucha et al., 2000). A 1.4 kb EcoRI-XhoI fragment of the zebrafish
dlx5a/dlx6a locus, which recapitulates with a high degree of preci-
sion the endogenous Dlx5 expression patterns in transgenic mice
(Zerucha et al., 2000), was placed into a plasmid containing the
Cre coding sequence downstream of a 3.5 kb fragment from the im-
mediate 50-flanking region of zebrafish dlx6a, including part of the
50UTR (Ghanem et al., 2003). The dlx6a upstream fragment does
not, by itself, produce any tissue-specific expression in transgenic
animals but was shown to increase the activity of theDlx5/Dlx6 inter-
genic enhancers. Transgenic mice (Dlx5/6-Cre) were produced as
previously described (Zerucha et al., 2000), and their spatial patterns
of Cre activity were determined by mating them with mice carrying
the Z/AP double reporter transgene (Lobe et al., 1999), Z/EG double
reporter transgene (Novak et al., 2000), and Rosa26 reporter trans-
gene (Soriano, 1999). Dlx5/6-Cre mice were crossed with CB1f/f
mice to obtain CB1f/f;Dlx5/6-Cre (here called GABA-CB12/2) and
CB1f/f littermate controls.
Induction of Acute Excitotoxic Seizures
KA was purchased from Ocean Produce International. Seizures were
induced by injecting 30 mg/kg of KA in 0.9% saline i.p. in a volume of
10 ml/kg body weight. Diazepam was purchased from Sigma, dis-
solved in saline, and injected s.c. at 20 ml/kg either 30 min before
the injection of KA or immediately after the appearance of first ob-
servable seizures (score 4, see below). Seizures were monitored
by a trained observer blind to the genotype or treatment of the
mice for 2 hr and scored every 15 min according to the following
scale (Marsicano et al., 2003; Schauwecker and Steward, 1997):
0—no response; 1—immobility and staring; 2—forelimb and/or tail
extension, rigid posture; 3—repetitive movements, head bobbing;
4—rearing and falling; 5—continuous rearing and falling: 6—severe
clonic-tonic seizures; 7—death.
Electrophysiology
For DSI experiments in the CA1 region (Wilson et al., 2001), sagittal
hippocampal slices (300 mm thick) were obtained from P21-30 mice
and maintained in artificial cerebrospinal fluid (ACSF) for at least
40 min prior to recording. The ACSF contained 125 mM NaCl,
1.25 mM NaH2PO4, 25 mM glucose, 2.5 mM KCl, 2.5 mM CaCl2,
2 mM MgCl2, 25 mM NaHCO3, 0.005 mM NBQX, 0.05 mM APV,
gassed with carbogen (95% O2/5% CO2) at 25
C. Neurons were re-
corded in the whole-cell voltage-clamp mode (holding potential,
260 mV), using electrodes (open tip resistance, 2–5 MU) filled with
a solution containing 100 mM CsCH3SO3, 60 mM CsCl, 10 mM
HEPES, 0.2 mM EGTA, 1 mM MgCl2, 1 mM MgATP, 0.3 mM Na3GTP,
5 mM QX-314, (pH 7.3; 275 mOsm). Recordings were accepted only
if the holding current was <100 pA. The current was low-pass filtered
at 1 kHz and digitized at 3 kHz. Inhibitory postsynaptic currents
(IPSCs) in CA1 pyramidal cells were evoked using a bipolar tungsten
electrode placed within the CA1 stratum radiatum. DSI tests con-
sisted of 30 stimuli at 0.33 Hz and a depolarization step to 0 mV
for 5 s after the thirteenth stimulus. DSI was calculated using the
mean of the five eIPSCs just before and after depolarization. For
studying the effects of CB1 activation on mossy cell-granule cell
synapses, sagittal hippocampal slices were obtained as described
above. Granule cells of the dentate gyrus were recorded using the
same extracellular and intracellular solutions as in DSI experiments,
with the following differences: the intracellular solution did not con-tain QX-314 and the ACSF did not contain any glutamate receptor in-
hibitor but, in order to isolate evoked excitatory postsynaptic gluta-
matergic currents (eEPSCs), contained the GABAA and GABAB
receptor antagonists bicuculline (10 mM) and CGP35348 (200 mM),
respectively. Granule cells were recorded from the middle part of
the dorsal ‘‘arm’’ of the dentate gyrus, and the electrode for stimula-
tion (square pulse stimuli at 0.066 Hz, 5–20V, 100 ms) was positioned
in their close vicinity (toward the septum) in the inner third of the mo-
lecular layer, where glutamatergic afferents to granule cell dendrites
belong in majority to mossy cell terminals (Johnston and Amaral,
2004) and partially to CA3 terminals (Li et al., 1994). WIN55,212-2
(5 mM, purchased from Tocris) was dissolved in DMSO and directly
added to the circulating ACSF at the indicated time points. The final
concentration of DMSO was 0.01%, and preliminary experiments
showed that this vehicle has no effect on eEPSCs. The reduction
of eEPSCs was calculated by comparing the mean of the last five
measurements before application of WIN55,212-2 (baseline) and
the last five measurements 40 min after application of the drug.
Evoked EPSCs were completely abolished by the application of
the glutamate receptor antagonists NBQX (5 mM) and APV (50 mM;
data not shown).
In Situ Hybridization
Single and double in situ hybridization were performed as described
(Marsicano et al., 2003; Marsicano and Lutz, 1999), using riboprobes
against mouse CB1 (Marsicano and Lutz, 1999), GAD65 (Marsicano
and Lutz, 1999), and VGluT1 (kind gift of Prof. Edwards, San Fran-
cisco, California; Fremeau et al., 2004). CB1 mRNA expression in
CB1f/f mice was not different from genetically wild-type C57BL/
6NCrlBR mice (data not shown). Cell counting was performed as
described in Marsicano and Lutz (1999). For quantification of
GAD65-CB1 mRNA coexpression, a total of 3027 cells were counted
in 22 hippocampal sections of CB1f/f and 2565 cells in 15 hippocam-
pal sections of Glu-CB12/2 mice. For quantification of VGluT1-CB1
mRNA coexpression in the hilus of dentate gyrus, a total of 624 cells
expressing low levels of CB1 mRNA (known as non-GABAergic neu-
rons, see Marsicano and Lutz [1999]) and of 642 cells expressing
VGluT1 mRNA were counted in 26 sections corresponding to the
hilus of dentate gyrus.
Immunohistochemistry
Single immunohistochemistry for CB1 protein in different condi-
tional mutants was performed as described (Egertova´ and Elphick,
2000). Semiquantitative evaluation of CB1 staining in the inner mo-
lecular layer of dentate gyrus was performed using the NIH Image
software as described (Marsicano et al., 2003). Double immunohis-
tochemistry for CB1 and VGluT1 was performed on 40 mm sections
from adult mouse brains prepared as described (Wager-Miller et al.,
2002), using an antibody raised in goat against the final 72 amino
acids of rat CB1 (Harka´ny et al., 2003) and a rabbit antibody against
VGluT1 (Synaptic Systems). Sections were imaged with a Leica SL
confocal microscope and processed using Adobe Photoshop. For
analyzing VGluT1 and CB1 colocalization, well-defined circular
structures were considered as terminals. A total of 2226 terminals
were counted in 24 fields corresponding to the inner third of the mo-
lecular layer of dentate gyrus.
Generation of Recombinant Adeno-Associated Virus
and Intrahilar Injections
The nuclear localization signal (nls) of the simian virus 40 large T an-
tigen and the Cre-recombinase coding region (Gu et al., 1993) was
fused downstream of the hemagglutinin (HA)-tag, in a rAAV plasmid
backbone containing the 1.1kb CMV immediate early enhancer/
chicken b-actin hybrid promoter (CBA), the woodchuck posttran-
scriptional regulatory element (WPRE; Paterna et al., 2000), and
the bovine growth hormone poly(A) (bGH) to obtain rAAV-CBA-
WPRE-bGH carrying Cre-recombinase (AAV-Cre). The rAAV-CBA-
WPRE-bGH backbone carrying the renilla GFP cDNA (Stratagene)
was used as negative control. rAAV chimeric vectors (virions con-
taining a 1:1 ratio of AAV1 and AAV2 capsid proteins with AAV2
ITRs) were generated as described (Klugmann et al., 2005). Briefly,
HEK293 cells were transfected with the AAV cis plasmid, the AAV1
and AAV2 helper plasmids, and the adenovirus helper plasmid by
standard calcium phosphate transfection methods. Sixty hours after
Endocannabinoids Control Epileptogenic Circuits
465transfection, cells were harvested and the vector purified using hep-
arin affinity columns (Sigma). Genomic titers were determined using
the ABI 7700 real time PCR cycler (Applied Biosystems) with primers
designed to WPRE (Clark et al., 1999). CB1f/f mice (6–9 weeks old at
the time of surgery) were anesthetized with isoflurane. One microliter
of either AAV-Cre or AAV-GFP (titres—2 3 1016 viral genomes/ml)
were bilaterally injected at 0.05 ml/min by glass capillaries with tip re-
sistance of 2-4 MU in a stereotactic apparatus, aiming at the dorsal
hilus of the dentate gyrus (Paxinos and Franklin, 2001; 1.6 mm pos-
terior to bregma, 1 mm lateral from midline, 1.8 mm below the sur-
face of the skull). Mice quickly recovered from surgery and were
tested 9 weeks after virus injection. Evaluation of the extension of
the deletion of CB1 mRNA was done on radioactive in situ hybridiza-
tion autoradiographic films containing sequential coronal sections
of AAV-GFP- and AAV-Cre-injected mice. Considering the normal
expression of CB1 in the forebrain (Marsicano and Lutz, 1999), the
extent of CB1 mRNA deletion in AAV-Cre-injected mice was approx-
imately calculated using coordinates from Paxinos and Franklin
(2001). Only data from mice bearing CB1 mRNA deletion limited
to the hippocampal formation were considered for analysis of
KA-induced seizures.
Statistical Analysis
Data from seizure scoring were analyzed using two-way ANOVA for
repeated measurements. Only statistical parameters referring to the
factor genotype or treatment are presented. Electrophysiological
data were analyzed by Student’s t test. Software Graph Pad Prism
4.0 was used for statistics and generation of graphs.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/51/4/455/DC1/.
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